Arcellx Corporate Presentation 2023 | Cell Therapy

Arcellx is a cell therapy company developing novel synthetic binding domain platforms including ddCAR and ARC-SparX for treating solid tumors and hematologic malignancies. The company reported a 100% overall response rate in a Phase 1 multiple myeloma study and has partnered with Kite to leverage commercial and manufacturing expertise.